万春医药上涨3.38%，报2.14美元/股，总市值8627.69万美元

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.38% on August 4, reaching $2.14 per share, with a total market capitalization of approximately $86.28 million [1] - As of June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net loss attributable to shareholders was $7.26 million, which represents a 42.91% increase compared to the previous year [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [2] - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]